Trends in treatment costs for localized prostate cancer: The healthy screenee effect

Medical Care

Volumn 45, Issue 2, 2007, Pages 154-159

  Zeliadt, Steven B ^a,b   Etzioni, Ruth ^a,b   Ramsey, Scott D ^a,b   Penson, David F ^a,c   Potosky, Arnold L ^d  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer attributable costs; Costs; Healthy screenee bias; Prostate; Prostatic neoplasms; SEER Medicare

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; ECONOMICS; HEALTH CARE COST; HUMAN; MALE; MASS SCREENING; MEDICARE; PROSTATE TUMOR;

AGED; HEALTH EXPENDITURES; HUMANS; MALE; MASS SCREENING; MEDICARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33846464623     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlr.0000241044.09778.3f     Document Type: Article

References (21)

1. Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40:104-117.
2. Saigal CS, Litwin MS. The economic costs of early stage prostate cancer. Pharmacoeconomics. 2002;20:869-878.
3. Leibman BD, Dillioglugil O, Abbas F, et al. Impact of a clinical pathway for radical retropubic prostatectomy. Urology. 1998;52:94-99.
4. Litwin MS, Smith RB, Thind A, et al. Cost-efficient radical prostatectomy with a clinical care path. J Urol. 1996;155:989-993.
5. Koch MO. Cost-efficient radical prostatectomy. Semin Urol Oncol. 1995;13:197-203.
6. Weiss NS, Rossing MA. Healthy screened bias in epidemiologic studies of cancer incidence. Epidemiology. 1996;7:319-322.
7. Baker MS, Kessler LG, Urban N, et al. Estimating the treatment costs of breast and lung cancer. Med Care. 1991;29:40-49.
8. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst. 1995;87:417-426.
9. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-3-IV-18.
10. Zeliadt SB, Potosky AL, Etzioni R, et al. Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology. 2004;64:1171-1176.
11. Brown ML, Riley GF, Potosky AL, et al. Obtaining long-term disease specific costs of care: application to Medicare enrollees diagnosed with colorectal cancer. Med Care. 1999;37:1249-1259.
12. Zeger SL, Liang KY. An overview of methods for the analysis of longitudinal data. Stat Med. 1992;11:1825-1839.
13. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267.
14. SEER*Stat: Surveillance Research Program, National Cancer Institute SEER*Stat software, version 5. 2.2, 2004. Available at: www.seer.cancer. gov/seerstat. Accessed September 1, 2006.
15. Zeliadt SB, Etzioni RD, Kristal AR. Estimated impact of the prostate cancer prevention trial on population mortality. Cancer. 2005;104:1556-1557.
16. Yabroff KR, Warren JL, Knopf K, et al. Estimating patient time costs associated with colorectal cancer care. Med Care. 2005;43:640-648.
17. Fryback DG, Craig BM. Measuring economic outcomes of cancer. J Natl Cancer Inst Monogr. 2004;33:134-141.
18. Morrison AS. Screening in Chronic Disease. New York, NY: Oxford University Press; 1985.
19. Jerant AF, Franks P, Jackson JE, et al. Age-related disparities in cancer screening: analysis of 2001 Behavioral Risk Factor Surveillance System data. Ann Fam Med. 2004;2:481-487.
20. Brandeis J, Pashos CL, Henning JM, et al. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer. 2000;89:1792-1799.
21. Burkhardt JH, Litwin MS, Rose CM, et al. Comparing the costs of radiation therapy and radical prostatectomy for the initial treatment of early-stage prostate cancer. J Clin Oncol. 2002;20:2869-2875.